Giles W. Slocum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Giles W. Slocum has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Gary Daniel Peksa
Rush University Medical Center, Chicago, IL, United States of America
3 shared publications - Michael Gottlieb
Department of Emergency Medicine Rush University Medical Center Chicago Illinois USA
3 shared publications Jaxson Burkins
Department of Pharmacy, Mount Sinai Hospital, Chicago, IL, USA
2 shared publications- Joshua M. DeMott
Rush University Medical Center, Chicago, IL, USA
2 shared publications - Kyle A. Weant
University of South Carolina College of Pharmacy Columbia South Carolina USA
2 shared publications - Nicole M. Acquisto
University of Rochester Medical Center Rochester New York USA
2 shared publications
Latest Publications
- Open Access
- 12 June 2026
- Published by Wiley in Academic Emergency Medicine
- Vol. 33 (6) , e70361
Gaps in Documenting Interpreter Service Utilization Among Emergency Department Clinicians Treating Patients With Limited English Proficiency
- 12 June 2026
- Published by Wiley in Academic Emergency Medicine
- Vol. 33 (6) , e70361
Open AccessGaps in Documenting Interpreter Service Utilization Among Emergency Department Clinicians Treating Patients With Limited English Proficiency
- 31 March 2025
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 93, 126-131
Impact of desmopressin on hematoma expansion in patients presenting to the emergency department on antiplatelet therapy
- 31 March 2025
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 93, 126-131
Impact of desmopressin on hematoma expansion in patients presenting to the emergency department on antiplatelet therapy
- 5 May 2024
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 81, 136-139
Doxycycline adherence for the management of Chlamydia trachomatis infections
- 5 May 2024
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 81, 136-139
Doxycycline adherence for the management of Chlamydia trachomatis infections
- 26 June 2022
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 59, 59-62
Clinical outcomes after 4F-PCC for warfarin-associated ICH and baseline GCS less than or equal to 8
- 26 June 2022
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 59, 59-62
Clinical outcomes after 4F-PCC for warfarin-associated ICH and baseline GCS less than or equal to 8
- 1 September 2020
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 3 (6) , 1048-1055
A cross-sectional survey of US hospital pharmacy leaders on departmental initiatives to address burnout
- 1 September 2020
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 3 (6) , 1048-1055
A cross-sectional survey of US hospital pharmacy leaders on departmental initiatives to address burnout
- 7 August 2020
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 77 (16) , 1284-1335
Key articles and guidelines for the emergency medicine clinical pharmacist: 2011-2018 update
To summarize recently published research reports and practice guidelines on emergency medicine (EM)–related pharmacotherapy. Our author group was composed of 14 EM pharmacists, who used a systematic process to determine main sections and topics for the update as well as pertinent literature for inclusion. Main sections and topics were determined using a modified Delphi method, author and peer reviewer groups were formed, and articles were selected based on a comprehensive literature review and several criteria for each author-reviewer pair. These criteria included the document “Oxford Centre for Evidence-based Medicine – Levels of Evidence (March 2009)” but also clinical implications, interest to reader, and belief that a publication was a “key article” for the practicing EM pharmacist. A total of 105 articles published from January 2011 through July 2018 were objectively selected for inclusion in this review. This was not intended as a complete representation of all available pertinent literature. The reviewed publications address the management of a wide variety of disease states and topic areas that are commonly found in the emergency department: analgesia and sedation, anticoagulation, cardiovascular emergencies, emergency preparedness, endocrine emergencies, infectious diseases, neurology, pharmacy services and patient safety, respiratory care, shock, substance abuse, toxicology, and trauma. There are many important recent additions to the EM-related pharmacotherapy literature. As is evident with the surge of new studies, guidelines, and reviews in recent years, it is vital for the EM pharmacist to continue to stay current with advancing practice changes.
- 7 August 2020
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 77 (16) , 1284-1335
Key articles and guidelines for the emergency medicine clinical pharmacist: 2011-2018 update
To summarize recently published research reports and practice guidelines on emergency medicine (EM)–related pharmacotherapy. Our author group was composed of 14 EM pharmacists, who used a systematic process to determine main sections and topics for the update as well as pertinent literature for inclusion. Main sections and topics were determined using a modified Delphi method, author and peer reviewer groups were formed, and articles were selected based on a comprehensive literature review and several criteria for each author-reviewer pair. These criteria included the document “Oxford Centre for Evidence-based Medicine – Levels of Evidence (March 2009)” but also clinical implications, interest to reader, and belief that a publication was a “key article” for the practicing EM pharmacist. A total of 105 articles published from January 2011 through July 2018 were objectively selected for inclusion in this review. This was not intended as a complete representation of all available pertinent literature. The reviewed publications address the management of a wide variety of disease states and topic areas that are commonly found in the emergency department: analgesia and sedation, anticoagulation, cardiovascular emergencies, emergency preparedness, endocrine emergencies, infectious diseases, neurology, pharmacy services and patient safety, respiratory care, shock, substance abuse, toxicology, and trauma. There are many important recent additions to the EM-related pharmacotherapy literature. As is evident with the surge of new studies, guidelines, and reviews in recent years, it is vital for the EM pharmacist to continue to stay current with advancing practice changes.
- 1 April 2020
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 38 (4) , 715-719
Factors associated with unsuccessful follow-up in patients undertreated for gonorrhea and chlamydia infections
- 1 April 2020
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 38 (4) , 715-719
Factors associated with unsuccessful follow-up in patients undertreated for gonorrhea and chlamydia infections
- 18 February 2019
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 39 (4) , 463-472
Glucagon for Relief of Acute Esophageal Foreign Bodies and Food Impactions: A Systematic Review and Meta‐Analysis
Glucagon is frequently used for the relief of esophageal impactions. This systematic review and meta‐analysis were performed to evaluate the efficacy and safety of glucagon for acute esophageal foreign body and food impactions. PubMed, CINAHL, Latin American and Caribbean Health Sciences Literature (LILACS), Scopus, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials were searched from inception to March 1, 2018. Retrospective, observational, and randomized controlled trials assessing glucagon for the relief of acute esophageal foreign body and food impaction were included. There were no language or age restrictions. Only studies conducted on humans and with a comparator (e.g., control or placebo) were included. Study quality analysis was performed using the Cochrane Risk of Bias tool. Quality of evidence analysis was performed using the Grading of Recommendations, Assessment, Development and Evaluations approach. A total of 1988 studies were identified, and five studies with a total of 1185 subjects were included. Treatment success occurred in 213 of 706 (30.2%) patients in the glucagon group and 158 of 479 (33.0%) patients in the control group (odds ratio [OR] 0.90, 95% confidence interval [CI] 0.69–1.17, p=0.42). There was minimal statistical heterogeneity (I2 = 14%, p=0.33). No publication bias was identified. Adverse events were identified in 24 (15.0%) patients in the glucagon group and 0 (0%) patients in the placebo group (risk difference [RD] 0.18, 95% CI 0.03‐0.33, p=0.02). Vomiting events occurred more frequently in the glucagon group (17 of 160 [10.6%] vs 0 of 53 [0%]) but was not statistically significant (RD 0.07, 95% CI ‐0.03‐0.17, p=0.19). Glucagon was not associated with a difference in treatment success but had a higher rate of adverse events for the treatment of esophageal foreign body and food impaction. Further controlled studies are needed to confirm the efficacy of glucagon with adequate power to assess adverse events.
- 18 February 2019
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 39 (4) , 463-472
Glucagon for Relief of Acute Esophageal Foreign Bodies and Food Impactions: A Systematic Review and Meta‐Analysis
Glucagon is frequently used for the relief of esophageal impactions. This systematic review and meta‐analysis were performed to evaluate the efficacy and safety of glucagon for acute esophageal foreign body and food impactions. PubMed, CINAHL, Latin American and Caribbean Health Sciences Literature (LILACS), Scopus, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials were searched from inception to March 1, 2018. Retrospective, observational, and randomized controlled trials assessing glucagon for the relief of acute esophageal foreign body and food impaction were included. There were no language or age restrictions. Only studies conducted on humans and with a comparator (e.g., control or placebo) were included. Study quality analysis was performed using the Cochrane Risk of Bias tool. Quality of evidence analysis was performed using the Grading of Recommendations, Assessment, Development and Evaluations approach. A total of 1988 studies were identified, and five studies with a total of 1185 subjects were included. Treatment success occurred in 213 of 706 (30.2%) patients in the glucagon group and 158 of 479 (33.0%) patients in the control group (odds ratio [OR] 0.90, 95% confidence interval [CI] 0.69–1.17, p=0.42). There was minimal statistical heterogeneity (I2 = 14%, p=0.33). No publication bias was identified. Adverse events were identified in 24 (15.0%) patients in the glucagon group and 0 (0%) patients in the placebo group (risk difference [RD] 0.18, 95% CI 0.03‐0.33, p=0.02). Vomiting events occurred more frequently in the glucagon group (17 of 160 [10.6%] vs 0 of 53 [0%]) but was not statistically significant (RD 0.07, 95% CI ‐0.03‐0.17, p=0.19). Glucagon was not associated with a difference in treatment success but had a higher rate of adverse events for the treatment of esophageal foreign body and food impaction. Further controlled studies are needed to confirm the efficacy of glucagon with adequate power to assess adverse events.
- Open Access
- 22 November 2018
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 2 (3) , 236-242
Implementation of a hemophilia management program improves clinical outcomes
- 22 November 2018
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 2 (3) , 236-242
Open AccessImplementation of a hemophilia management program improves clinical outcomes
- Open Access
- 1 January 2018
- Published by Taylor & Francis in Toxicology Communications
- Vol. 2 (1) , 19-20
Pregabalin and paradoxical reaction of seizures in a large overdose
We report the case of a 54-year-old female with intentional pregabalin 3825 mg ingestion that resulted in a rare adverse effect of a witnessed seizure with confirmatory serum concentrations. After presenting alert to the emergency department she became obtunded, only responding to sternal rub (four hours after ingestion). Laboratory evaluation and toxicology panel were unremarkable. Approximately eight hours after the ingestion she had physician-witnessed tonic–clonic seizure activity with right gaze deviation for 90 seconds. This is only the third documented case of paradoxical seizure due to a large overdose of pregabalin. Also, the serum concentration observed is among the highest recorded (58 mcg/mL five hours post-ingestion). Pregabalin abuse has been emerging. Clinical toxicologists should be aware of the potential of pregabalin-induced seizures following overdose.
- 1 January 2018
- Published by Taylor & Francis in Toxicology Communications
- Vol. 2 (1) , 19-20
Open AccessPregabalin and paradoxical reaction of seizures in a large overdose
We report the case of a 54-year-old female with intentional pregabalin 3825 mg ingestion that resulted in a rare adverse effect of a witnessed seizure with confirmatory serum concentrations. After presenting alert to the emergency department she became obtunded, only responding to sternal rub (four hours after ingestion). Laboratory evaluation and toxicology panel were unremarkable. Approximately eight hours after the ingestion she had physician-witnessed tonic–clonic seizure activity with right gaze deviation for 90 seconds. This is only the third documented case of paradoxical seizure due to a large overdose of pregabalin. Also, the serum concentration observed is among the highest recorded (58 mcg/mL five hours post-ingestion). Pregabalin abuse has been emerging. Clinical toxicologists should be aware of the potential of pregabalin-induced seizures following overdose.